blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1440152

EP1440152 - 5T4 LIGAND [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.02.2014
Database last updated on 02.11.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Oxford Biomedica (UK) Limited
Medawar Centre, Robert Robinson Avenue, The Oxford Science Park
Oxford OX4 4GA / GB
[2013/17]
Former [2004/31]For all designated states
Oxford Biomedica (UK) Limited
Medawar Centre, Robert Robinson Avenue, The Oxford Science Park
Oxford 0X4 4GA / GB
Inventor(s)01 / CARROLL, Miles, Oxford BioMedica (UK) Limited
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA / GB
02 / LAMIKANRA, Abigail, Oxford BioMedica (UK) Limited
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA / GB
03 / KINGSMAN, Alan, Oxford BioMedica (UK) Limited
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA / GB
 [2013/17]
Former [2004/31]01 / CARROLL, Miles, Oxford BioMedica (UK) Limited
Medawar Centre, Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA / GB
02 / LAMIKANRA, Abigail, Oxford BioMedica (UK) Limited
Medawar Centre, Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA / GB
03 / KINGSMAN, Alan, Oxford BioMedica (UK) Limited
Medawar Centre, Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA / GB
Representative(s)Harding, Charles Thomas, et al
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
[N/P]
Former [2013/17]Harding, Charles Thomas, et al
D Young & Co LLP 120 Holborn London
EC1N 2DY / GB
Former [2009/26]Harding, Charles Thomas, et al
D Young & Co 120 Holborn London
EC1N 2DY / GB
Former [2008/24]Harding, Charles Thomas, et al
D Young & Co 120 Holborn
London EC1N 2DY / GB
Former [2004/31]Maschio, Antonio, Dr.
D Young & Co, 21 New Fetter Lane
London EC4A 1DA / GB
Application number, filing date02772604.104.11.2002
[2004/31]
WO2002GB04965
Priority number, dateGB2001002637802.11.2001         Original published format: GB 0126378
[2004/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03038098
Date:08.05.2003
Language:EN
[2003/19]
Type: A2 Application without search report 
No.:EP1440152
Date:28.07.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 08.05.2003 takes the place of the publication of the European patent application.
[2004/31]
Type: B1 Patent specification 
No.:EP1440152
Date:24.04.2013
Language:EN
[2013/17]
Search report(s)International search report - published on:EP12.06.2003
ClassificationIPC:C12N15/13, C12N15/62, G01N33/50, A61K39/395, C07K16/28
[2004/31]
CPC:
C07K16/28 (EP,US); C07K16/30 (US); C07K2317/77 (EP,US);
C07K2319/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2004/31]
TitleGerman:5T4 LIGAND[2004/31]
English:5T4 LIGAND[2004/31]
French:5T4 LIGAND[2004/31]
Entry into regional phase24.05.2004National basic fee paid 
24.05.2004Designation fee(s) paid 
24.05.2004Examination fee paid 
Examination procedure24.02.2003Request for preliminary examination filed
International Preliminary Examining Authority: EP
24.05.2004Examination requested  [2004/31]
09.05.2008Despatch of a communication from the examining division (Time limit: M06)
08.09.2008Reply to a communication from the examining division
13.08.2009Despatch of a communication from the examining division (Time limit: M06)
19.02.2010Reply to a communication from the examining division
03.02.2011Despatch of a communication from the examining division (Time limit: M04)
16.05.2011Reply to a communication from the examining division
28.11.2011Despatch of a communication from the examining division (Time limit: M04)
20.02.2012Reply to a communication from the examining division
25.09.2012Cancellation of oral proceeding that was planned for 16.10.2012
16.10.2012Date of oral proceedings (cancelled)
13.11.2012Communication of intention to grant the patent
18.03.2013Fee for grant paid
18.03.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.05.2008
Opposition(s)27.01.2014No opposition filed within time limit [2014/14]
Fees paidRenewal fee
08.11.2004Renewal fee patent year 03
14.11.2005Renewal fee patent year 04
14.11.2006Renewal fee patent year 05
12.11.2007Renewal fee patent year 06
26.03.2008Renewal fee patent year 07
17.11.2009Renewal fee patent year 08
15.11.2010Renewal fee patent year 09
28.11.2011Renewal fee patent year 10
14.11.2012Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY24.04.2013
CZ24.04.2013
EE24.04.2013
FI24.04.2013
MC24.04.2013
SE24.04.2013
SK24.04.2013
TR24.04.2013
BG24.07.2013
GR25.07.2013
PT26.08.2013
LU04.11.2013
[2015/34]
Former [2015/32]CY24.04.2013
CZ24.04.2013
EE24.04.2013
FI24.04.2013
MC24.04.2013
SE24.04.2013
SK24.04.2013
TR24.04.2013
BG24.07.2013
GR25.07.2013
PT26.08.2013
Former [2014/33]CY24.04.2013
CZ24.04.2013
EE24.04.2013
FI24.04.2013
MC24.04.2013
SE24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
PT26.08.2013
Former [2014/10]CY24.04.2013
CZ24.04.2013
EE24.04.2013
FI24.04.2013
SE24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
PT26.08.2013
Former [2013/52]CY24.04.2013
FI24.04.2013
SE24.04.2013
BG24.07.2013
GR25.07.2013
PT26.08.2013
Former [2013/50]FI24.04.2013
SE24.04.2013
BG24.07.2013
GR25.07.2013
PT26.08.2013
Former [2013/49]FI24.04.2013
SE24.04.2013
GR25.07.2013
PT26.08.2013
Former [2013/47]PT26.08.2013
Cited inInternational search[X]WO0136486  (OXFORD BIOMEDICA LTD [GB], et al) [X] 1-3,6,8,10-12,14-16,18-20,22-25,27-29,31,32,34,35,37,38,40-44 * page 76 - page 77; figures 1-4,14,19,25 * * page 83 - page 84; example 1 *;
 [T]  - MYERS K A ET AL, "TARGETING IMMUNE EFFECTOR MOLECULES TO HUMAN TUMOR CELLS THROUGH GENETIC DELIVERY OF 5T4-SPECIFIC SCFV FUSION PROTEINS", CANCER GENE THERAPY, NORWALK, CT, US, (200211), vol. 9, no. 11, ISSN 0929-1903, pages 884 - 896, XP009007160

DOI:   http://dx.doi.org/10.1038/sj.cgt.7700513
 [X]  - FORSBERG G ET AL, "THERAPY OF HUMAN NON-SMALL-CELL LUNG CARCINOMA USING ANTIBODY TARGETING OF A MODIFIED SUPERANTIGEN", BRITISH JOURNAL OF CANCER, LONDON, GB, (20010706), vol. 85, no. 1, ISSN 0007-0920, pages 129 - 136, XP001145660 [X] 1-3,6,8,10-12,14-16,18-20,22-25,27-29,31,32,34,35,37,38,40-44 * page 130; figure 1 * * page 134 - page 135 *

DOI:   http://dx.doi.org/10.1054/bjoc.2001.1891
 [DA]  - SHAW^A D M ET AL, "Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4", BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, (20001215), vol. 1524, no. 2-3, ISSN 0304-4165, pages 238 - 246, XP004275928

DOI:   http://dx.doi.org/10.1016/S0304-4165(00)00165-3
 [A]  - MYERS K A ET AL, "ISOLATION OF A CDNA ENCODING 5T4 ONCOFETAL TROPHOBLAST GLYCOPROTEIN", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (19940325), vol. 269, no. 12, ISSN 0021-9258, pages 9319 - 9324, XP002064468
Examination   - VELDEN VAN DER V ET AL, "Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells", Blood, Washington, USA, (20010515), vol. 97, no. 10, pages 3197 - 3204, XP009080680

DOI:   http://dx.doi.org/10.1182/blood.V97.10.3197
    - BERNT K ET AL, "CD19 targeted calicheamicin THETA is effective against high risk ALL", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20001116), Database accession no. PREV200100330624
    - BOGHAERT E R ET AL, "The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin", INTERNATIONAL JOURNAL OF ONCOLOGY, (200801), vol. 32, no. 1, doi:doi:10.3892/ijo.32.1.221, ISSN 1019-6439, pages 221 - 234, XP055051976

DOI:   http://dx.doi.org/10.3892/ijo.32.1.221
    - SANDVIG K ET AL, "Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (20001115), vol. 19, no. 22, doi:10.1093/EMBOJ/19.22.5943, ISSN 0261-4189, pages 5943 - 5950, XP002228667

DOI:   http://dx.doi.org/10.1093/emboj/19.22.5943
    - SVETLANA O. DORONINA ET AL, "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity", BIOCONJUGATE CHEMISTRY, (20060101), vol. 17, no. 1, doi:10.1021/bc0502917, ISSN 1043-1802, pages 114 - 124, XP055009264

DOI:   http://dx.doi.org/10.1021/bc0502917
    - TSUTA K ET AL, "Using the Mitosis-Specific Marker Anti-Phosphohistone H3 to Assess Mitosis in Pulmonary Neuroendocrine Carcinomas", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, (201108), vol. 136, doi:10.1309/AJCPDXFOPXGEF0RP, ISSN 0002-9173, pages 252 - 259
by applicantUS239400
 US4376110
 EP0239400
 WO8907947
 EP0368684
 EP0436597
 EP0623679
 JP2501886B
 WO0029428
    - MYERS ET AL., J BIOL CHEM, (1994), vol. 169, pages 9319 - 24
    - STARZYNSKA ET AL., EUR J GASTROENTEROL HEPATOL, (199806), vol. 10, no. 6, pages 479 - 84
    - STARZYNSKA ET AL., BR J CANCER, (199405), vol. 69, no. 5, pages 899 - 902
    - STARZYNSKA ET AL., BR J CANCER, (199211), vol. 66, no. 5, pages 867 - 9
    - PARKER, K. C ET AL., J. IMMUNOL., (1994), vol. 152, page 163
    - PARKER, K. C ET AL., J.IMMUNOL., (1994), vol. 152, page 163
    - ALTSCHUL ET AL., NATURE GENETICS, (1994), vol. 6, pages 119 - 129
    - CANCER RES, (1993), vol. 53, pages 851 - 856
    - NATURE, (1988), vol. 332, pages 323 - 327
    - SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - PROC NATL ACAD SCI USA, (1991), vol. 88, pages 4181 - 4185
    - J IMMUNOL, (1992), vol. 148, pages 1149 - 1154
    - BIOCHIM BIOPHYS ACTA, (20001215), vol. 1524, no. 2-3, pages 238 - 46
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1984), vol. 81, page 6851
    - NEUBERGER ET AL., NATURE, (1985), vol. 314, page 268
    - NISHIMURA ET AL., CANCER RES., (1987), vol. 47, page 999
    - DORAI ET AL., J. IMMUNOL., (1987), vol. 139, page 4232
    - KAMEYAMA ET AL., FEBS LETTER, (1989), vol. 244, page 301
    - GILLIES ET AL., J. IMMUNOL. METHODS, (1989), vol. 125, page 191
    - WINTER, G.; MILSTEIN, C., NATURE, (1991), vol. 349, pages 293 - 299
    - KANG, PROC. NATL. ACAD. SCI. US.A., (1991), vol. 88, page 4363
    - CLACKSON ET AL., NATURE, (1991), vol. 352, page 624
    - LOWMAN ET AL., BIOCHEMISTRY, (1991), vol. 30, page 10832
    - BURTON ET AL., PROC. NATL. ACAD. SCI U.S.A., (1991), vol. 88, page 10134
    - HOOGENBOOM ET AL., NUCLEIC ACIDS RES., (1991), vol. 19, page 4133
    - CHANG, J. IMMUNOL., (1991), vol. 147, page 3610
    - BREITLING ET AL., GENE, (1991), vol. 104, page 147
    - HAWKINS; WINTER, J 1MMUNOL., (1992), vol. 22, page 867
    - MARKS ET AL., J. BIOL. CHEM., (1992), vol. 267, page 16007
    - LERNER ET AL., SCIENCE, (1992), vol. 258, page 1313
    - WINTER; MILSTEIN, NATURE, (1991), vol. 349, pages 293 - 299
    - PLUECKTHUN, IMMUNOLOGICAL REVIEWS, (1992), vol. 130, pages 151 - 188
    - WRIGHT ET AL., CRTI. REV. IMMUNOL., (1992), vol. 12, pages 125 - 168
    - HOLLIGER, P.; WINTER, G., CURR. OP. BIOTECHN., (1993), vol. 4, pages 446 - 449
    - CARTER ET AL., J. HEMATOTHER., (1995), vol. 4, pages 463 - 470
    - CHESTER, K.A.; HAWKINS, R.E., TRENDS BIOTECHN., (1995), vol. 13, pages 294 - 300
    - HOOGENBOOM, H.R., NATURE BIOTECHNOL., (1997), vol. 15, pages 125 - 126
    - FEARON, D., NATURE BIOTECHNOL., (1997), vol. 15, pages 618 - 619
    - PLÜCKTHUN, A.; PACK, P., IMMUNOTECHNOLOGY, (1997), vol. 3, pages 83 - 105
    - CARTER, P.; MERCHANT, A.M., CURR. OPIN. BIOTECHNOL., (1997), vol. 8, pages 449 - 454
    - HOLLIGER, P.; WINTER, G., CANCER IMMUNOL. IMMUNOTHER, (1997), vol. 45, pages 128 - 130
    - KESTLER ET AL., HUMAN GENE THER, (1999), vol. 10, no. 10, pages 1619 - 32
    - WORLD J SURG, (200207), vol. 26, no. 7, pages 783 - 9
    - ADV EXP MED BIOL, (2000), vol. 465, pages 411 - 22
    - SEMIN ONCOL., (199602), vol. 23, no. 1, pages 31 - 45
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.